ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ASND Ascendis Pharma AS

151.17
2.73 (1.84%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 295,063
Bid Price 145.48
Ask Price 156.31
News -
Share Name Share Symbol Market Stock Type
Ascendis Pharma AS ASND NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
2.73 1.84% 151.17 19:00:00
Open Price Low Price High Price Close Price Previous Close
149.15 144.66 151.59 151.17 148.44
Trades Shares Traded VWAP Financial Volume Average Volume
5,865 295,063  148.40  43,788,680 -
Last Trade Type Quantity Price Currency
15:55:56 14  151.50 USD

Ascendis Pharma AS (ASND) Options Flow Summary

Overall Flow

Bullish

Net Premium

41k

Calls / Puts

200.00%

Buys / Sells

0.00%

OTM / ITM

200.00%

Sweeps Ratio

0.00%

Ascendis Pharma AS Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 0.00 - 200.64M -481.45M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Ascendis Pharma AS

Date Time Source Heading
3/07/202410:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
3/05/202420:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
3/05/202407:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
3/05/202407:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
3/05/202406:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
3/04/202414:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
3/04/202414:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
3/04/202413:54Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
3/04/202413:36Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
3/04/202407:30GlobeNewswire Inc.Ascendis Pharma to Participate in the Leerink Partners..
3/01/202410:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
2/29/202416:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ASND Message Board. Create One! See More Posts on ASND Message Board See More Message Board Posts

ASND Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Your Recent History

Delayed Upgrade Clock